Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 9,100 shares at $18.95 ($172K) on 2022-12-08, disclosed to the SEC on 2022-12-12.
Open-market sale of $172k TRDA by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.95 | 4,550 | $86K | 50.0% |
| 2 | $18.95 | 4,550 | $86K | 50.0% |
| Total | $18.95 avg | 9,100 | $172K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |